A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

drug protocol number
ITCA 650-CLP-105
drug sponsor
Intarcia Therapeutics
drug study
ITCA 650
drug trial site
NGHA-J
drug status
Completed
drug phase